ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Study of Disease Progression and Anti-HIV Treatments

This study has been completed.

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00001068
  Purpose

To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.


Condition Intervention Phase
HIV Infections
Drug: Lamivudine
Phase II

MedlinePlus related topics:   AIDS   

Drug Information available for:   Zidovudine    Lamivudine    Didanosine    Zalcitabine   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-Up Study to ACTG 175

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:   210

  Eligibility
Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

Patients must have:

  • Prior participation on protocol ACTG 175.

PER AMENDMENT 8/27/96:

  • Patients must be on study/on treatment at the time the protocol study treatment is extended.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001068

Show 59 study locations  Show 59 Study Locations

Sponsors and Collaborators
  More Information


Publications:

Study ID Numbers:   ACTG 303
First Received:   November 2, 1999
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00001068
Health Authority:   United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Zalcitabine  
Didanosine  
Drug Therapy, Combination  
AIDS-Related Complex  
Antiviral Agents
Zidovudine
Lamivudine

Study placed in the following topic categories:
Sexually Transmitted Diseases, Viral
Acquired Immunodeficiency Syndrome
Zalcitabine
Disease Progression
Zidovudine
Lamivudine
AIDS-Related Complex
Immunologic Deficiency Syndromes
Virus Diseases
Didanosine
HIV Infections
Sexually Transmitted Diseases
Retroviridae Infections

Additional relevant MeSH terms:
Anti-Infective Agents
RNA Virus Infections
Disease Attributes
Anti-HIV Agents
Slow Virus Diseases
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Infection
Antiviral Agents
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Pathologic Processes
Anti-Retroviral Agents
Therapeutic Uses
Lentivirus Infections
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers